Edited by: Michael Tipton
Introduction
Physical exercise is considered to be the most effective non-pharmacological strategy promoting cardiovascular and metabolic health benefits (Serrano et al. 2008; Lang et al. 2010; Viña et al. 2016) . Over the years, the effects of different exercise models have been extensively studied to investigate mechanisms underlying adaptations of human skeletal muscle to both endurance (Fluck, 2006) and resistance exercises (Deschenes & Kraemer, 2002) . Recently, in vitro approaches using skeletal muscle cells have been developed in order to elucidate mechanisms responsible for exercise-induced adaptations (Lambernd et al. 2012; Nikolić et al. 2012; Scheler et al. 2013) . It has been suggested that electrical pulse stimulation (EPS) of muscle cells is an in vitro exercise model mimicking in vivo muscle adaptations (Nedachi et al. 2008; Manabe et al. 2012; Nikolić et al. 2012) . By combining different pulse stimulation variables (output voltage, frequency and duration of pulse trains), the EPS model offers a wide range of stimulation protocols inducing contraction of skeletal muscle cells. Recent studies have demonstrated EPS-induced exercise-related responses including lactate release (Lambernd et al. 2012; Scheler et al. 2013; Nikolić et al. 2017) , reduced ATP and phosphocreatine concentations (Nedachi et al. 2008; Nikolić et al. 2012) , increased oxidative capacity (Nedachi et al. 2008; Burch et al. 2010; Feng et al. 2015) and improved insulin sensitivity (Lambernd et al. 2012; Feng et al. 2015) . Together, these findings suggest that EPS is a physiologically relevant ex vivo model recapitulating metabolic changes that occur in human skeletal muscles in response to exercise. Nevertheless, to our knowledge, whether EPS is an in vitro exercise model promoting the hypertrophy of human skeletal muscle cells has never been addressed. It is therefore important to establish an in vitro exercise model, where the promotion of hypertrophic phenotype can be evidenced by the enlargement of muscle cells, which is a main physiological end-point. We hypothesized that the enlargement of myotubes would occur in the resting period after the completion of EPS, because in vivo adaptations to resistance exercise in humans are observed after and not during training sessions.
Given the discussion above, the primary goal of the present study was to establish an in vitro EPS model promoting the hypertrophy of human muscle cells, a major physiological end-point to resistance exercise in human skeletal muscle.
Methods
Ethical approval. Informed consent was obtained before participation in the study, and all procedures conformed to the standards set by the latest revision of the Declaration of Helsinki, except for registration in a database. Ethical approval was obtained from the regional Ethical Review Board in Uppsala (DNR 2015/489).
Isolation and purification of human myoblasts. Muscle biopsies were obtained from the mid-portion of vastus lateralis in healthy volunteers (four males and one female; age 35.6 ± 5.3 years). Explants were scissor minced and trapped inside a layer of 6 mg ml
Matrigel (Matrigel Matrix; BD Biosciences, Le Pont de Claix, France) with growth medium [Dulbecco's modified Eagle Medium (DMEM); Sigma Aldrich, Sweden], supplemented with 20% fetal bovine serum, 0.5% Ultroser G (Pall Corporation, Saint-Germain-en-Laye, France), 10 mM Hepes (H0887; Sigma Aldrich) and 50 μg ml −1 gentamicin (G1397; Sigma Aldrich). After 6-15 days of culture, migrating cells were enzymatically harvested using dispase (BD Biosciences) and purified immunomagnetically using magnetic-activated cell sorter (MACS) microbeads coupled to CD56 antibody (Miltenyi Biotec, Paris, France; Barro et al. 2010; Wåhlin-Larsson et al. 2014) . At purification, human myoblasts were considered to be at one population doubling (PD), and all experiments were performed at PD 4.
Electrical pulse stimulation. Myoblasts were seeded at 1 × 10 5 cells per dish onto collagen type I-coated six-well plates (Corning Life Sciences, Schiphol-Rijk, The Netherlands) and grown in proliferation medium (DMEM with 20% fetal bovine serum and 0.5% Ultroser G). All experimental incubations were performed in a 37°C humid air incubator containing 5% CO 2 . At 80% confluence, growth medium was replaced with DMEM containing 2% fetal bovine serum to induce myogenic differentiation. Muscle cells were fully differentiated during 48 h, and EPS using a C-Pace EP multichannel culture pacer (IonOptix, Dublin, Ireland) was then applied for 8 h, with a protocol consisting of 2 ms pulses at 12 V, with a frequency of 1 Hz. After completion of EPS, a restitution period of 8 h was applied. By 48 h of differentiation, multinucleated myotubes were formed, and no further fusion contributing to diameter increase was observed. The EPS protocol did not induce any visible cell detachment, and assessment of the cytotoxic effect of EPS based on the release of lactate dehydrogenase in culture media using a colorimetric cytotoxicity assay (CytoTox 96; Promega, Finnboda, Nacka, Sweden) showed that lactate dehydrogenase activity was unchanged in medium from stimulated compared with unstimulated myotubes.
We hypothesized that the morphological response (myotube hypertrophy) would occur in the resting period after cessation of EPS because in vivo adaptations to resistance exercise in humans are observed after and not during training sessions. In order to test our hypothesis, the size of the myotubes was analysed immediately after the EPS protocol (0 h) and after a resting period of 4 and 8 h after EPS. The morphology of non-stimulated myotubes (CON myotubes) was determined at the same time points. To assess whether an increased rate of protein synthesis is essential for EPS-induced hypertrophy, myotubes were exposed to the global protein inhibitor, cycloheximide (CHX). Differentiated myotubes were incubated in differentiation medium without (CON) or with CHX (100 μM) and exposed to the EPS protocol.
Immunohistochemistry. Myotubes were fixed with 2% paraformaldehyde and permeabilized with 0.25% Triton X-100 (Sigma Aldrich) followed by incubation with primary antibodies against myogenin (1:200; rabbit polyclonal, ab82843; Abcam, Cambridge, UK) and troponin T (1:100; mouse monoclonal, MS-295-P; Thermo Fisher Scientific, Waltham, MA, USA). Fluorescent labelled Alexa 488 (1:100; goat anti-mouse; Thermo Fisher Scientific) and Alexa 568 (1:100; goat anti-rabbit; Thermo Fisher Scientific) secondary antibodies were used. Nuclei were stained blue using 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (Thermo Fisher Scientific). Cells were visualized with a fluorescence microscope (Zeiss Axiovert; Carl Zeiss AG, Oberkochen, Germany), and image acquisition was performed using ZEN Microscope software (Carl Zeiss AG). Approximately 10 fields within each well were selected, and at least 120 myotubes were included in the analysis. The mean of five measurements along the length of each myotube was used to calculate the average diameter per myotube. The myogenic fusion index was defined as the ratio between the number of myonuclei within and outside myotubes in a given microscopic field. An average of 1500 myonuclei per dish were counted. Morphological analyses were performed using ImageJ Software (US National Institutes of Health, Bethesda, MD, USA).
Western blot analysis. Cells were rinsed with PBS and lysed in buffer containing 50 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, 10 mM β-glycerophosphate, 50 mM NaF, 0.5 mM sodium orthovanadate and a protease inhibitor tablet (Roche Applied Science, Penzberg, Germany). Equal amounts of protein (10 μg) from cell lysates prepared in Laemmli buffer were separated on 8-12% SDS-polyacrylamide gels at 200 V for 70-90 min and subsequently transferred to nitrocellulose membranes at 100 V for 60 min (Mini Trans-Blot Electrophoretic Transfer Cell; Bio-Rad, Göteborg, Sweden). A blocking step for 1 h at room temperature with 5% non-fat dry milk was followed by the incubation with primary antibodies (1:1000; Cell Signaling Technology, Leiden, The Netherlands) against phosphorylated mammalian target of rapamycin (phospho-mTOR; Ser2448, catalogue no. #5536), phospho-4E-BP1 (Thr37/46, catalogue no. #9459), phosphorylated AMP-activated protein kinase (phospho-AMPK; Thr172, catalogue no. #4188) and phospho-P70 S6K1 (Thr389, catalogue no. #9234). Horseradish peroxidase-conjugated anti-rabbit secondary antibody (1:2000; Cell Signaling Technology) was used to detect primary antibody binding. All blots were normalized to β-actin (catalogue no. #4967; Cell Signaling Technology). Membranes were treated with chemiluminescent horseradish peroxidase substrate (LI-COR Biosciences, Lincoln, NE, USA) to visualize bands, and Image Studioۛ Software (Li-Cor Biotechnology, Lincoln, NE, USA) was used for quantification of band intensities.
Interleukin-6 (IL-6) release. Time course analysis of IL-6 secretion in culture medium was performed using a Human IL-6 Standard TMB ELISA Development Kit (catalogue no. 900-T16, detection range 8-2000 pg ml −1 ; PeproTech, Stockholm, Sweden) according to the manufacturer's instructions. Conditioned medium was collected during (1 and 4 h) and after cessation of EPS (+0, +1 and +4 h). All analyses were performed in triplicate.
Gene expression analysis. Total RNA was extracted using the NucleoSpin R RNA Isolation Kit (Macherey-Nagel, Düren, Germany). The quantity of the RNA was determined on a NanoDrop 2000 (Thermo Fisher Scientific). The RNA was reverse transcribed using High Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Carlsbad, CA, USA). Real-time PCR was performed using Taqman R Fast Universal PCR Master Mix (2X; Applied Biosystems) with gene-specific primers for myostatin (Hs00976237 m1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Hs03929097 g1; Applied Biosystems). Rotor Gene Q (Qiagen, Hilden, Germany) was used for the amplifications of PCRs, consisting of an initial hold phase (at 95°C for 20 s) followed by 40-50 cycles of 1 s at 95°C and 20 s at 60°C. Gene expression levels were normalized to GAPDH and analysed using C T .
Statistical analyses. Analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA). Data are presented as the median (interquartile range). The Wilcoxon signed-rank test was used to determine differences between CON and EPS conditions. Time course analysis of IL-6 was assessed using the Friedman test. The significance level was set at P < 0.05.
Results
Multinucleated myotubes were exposed to the following EPS protocol: pulses of 2 ms with 12 V at a frequency of 1 Hz for 8 h. Electrical pulse stimulation-induced contraction of differentiated myotubes is available as supplementary material (Video S1). We first sought to determine the time course of EPS-mediated release of IL-6, an important exercise-induced myokine. Interleukin-6 secretion was assessed during EPS (1 and 4 h) and after completion of EPS (+0, +1 and +4 h). We showed that EPS induced the release of IL-6. Compared with baseline (1 h EPS), IL-6 secretion in stimulated myotubes (EPS myotubes) became significant 1 h after completion of EPS (P = 0.01), with a peak level reached 4 h after cessation of EPS (P = 0.007; Fig. 1 ). In contrast, IL-6 secretion in CON myotubes was below the detection threshold throughout the experimental time course.
In accordance with our hypothesis regarding the time of occurrence of the physiological end-point, significant increases in myotube diameter (EPS myotubes 31 ± 14% larger than CON myotubes; P = 0.03) occurred in response to the EPS protocol followed by an 8 h resting period (EPS + 8 h), but not immediately (EPS + 0 h) or 4 h after completion of EPS (EPS + 4 h; Fig. 2A and B) . Moreover, there was no significant difference in myogenic fusion index between EPS myotubes and CON myotubes (Fig. 3) , indicating that EPS-mediated hypertrophy occurred in already fully differentiated myotubes.
In order to provide additional information about molecular events preceding the physiological end-point (enlargement of muscle cells), we examined the effect of EPS on selected factors known to be involved in the regulation of skeletal muscle hypertrophy. Immunoblot analyses showed significant increases of phosphorylated mTOR (P = 0.03; Fig. 4A ) and its downstream target 4E-BP1 (P = 0.01, Fig. 4B ), two key factors of the Akt/mTOR growth signalling pathway regulating protein accretion. In line with this, we also demonstrated that inhibition of protein synthesis using CHX prevented hypertrophy of EPS myotubes (Fig. 2C) . We did not detect significant changes at the level of phosphorylated p70S6k1 (Fig. 4C) . Importantly, there were no significant EPS-induced changes in AMPK, a sensor of cellular energy status able to inhibit the Akt/mTOR pathway (Fig. 4D) . In the present study, we also addressed early changes in gene expression of the negative regulator of muscle mass, myostatin. A significant, 20% downregulation (P = 0.04) of myostatin occurred at 4 h after the start of EPS.
Discussion
Electrical pulse stimulation has previously been used as an in vitro exercise model offering the possibility of depicting complex cellular and molecular adaptations of skeletal muscle to exercise. The main goal of the present work was to establish an EPS-based cell culture model that induces the hypertrophy of human muscle cells, thereby recapitulating a major physiological end-point to resistance exercise. Therefore, the primary end-point of the present report was the morphological enlargement of myotube size. We hypothesized that allowing muscle cells to rest after EPS might be essential for the induction of the morphological change, because adaptations to resistance exercise in human skeletal muscles occur after and not during the exercise bout (Dreyer et al. 2006; Kumar et al. 2009; Atherton et al. 2017) . Previous studies using similar stimulation parameters to those used in our report have shown that EPS is not associated with increased cell toxicity (Lambernd et al. 2012; Scheler et al. 2013) . In response to our EPS model, lactate dehydrogenase release did not increase in stimulated myotubes and there was no visible cell detachment, and the occurrence of cell enlargement indicates that our protocol did not confer major cellular damage. A new finding in our study is that adding a resting period of 8 h after EPS is a crucial parameter for the induction of myotube hypertrophy, because increases in myotube size did not occur immediately or 4 h after completion of EPS. Our data are supported by previous studies showing signs of increased formation of striated sarcomeric structures in response to EPS (Fujita et al. 2007; Lambernd et al. 2012) . Interestingly, the use of human muscle cells obtained from different donors revealed between-donor differences in the myotrophic response to EPS ranging from +21 to +43% of hypertrophy. The use of human donors instead of cell lines allows evaluation of biological variability in response to a given stimulus. This is particularly relevant in the context of the present study, because an -rank test) . B, troponin T immunofluorescent labelled EPS myotubes and CON myotubes at EPS + 8 h resting period. Scale bar represents 100 μm. C, boxplot showing size of CON myotubes and EPS myotubes exposed to cycloheximide (EPS + CHX) at EPS + 8 h resting period; n = 5; * P < 0.05 (Wilcoxon signed-rank test).
important principle related to the physiological response of humans to exercise is the occurrence of inter-individual variability in the response to a similar physiological stimulus. Thus, our in vitro EPS-based approach to induce hypertrophy of human muscle cells provides a biologically relevant tool to mimic in vivo physiological variability in response to an anabolic stimulus, which is useful for future investigations addressing mechanisms controlling the hypertrophic process. Skeletal muscle is an endocrine organ associated with the release of several myokines in response to exercise (Nedachi et al. 2008; Raschke et al. 2013 ). Interleukin-6 is known to be an important contraction-regulated myokine released by muscle cells in response to exercise in vivo (Keller et al. 2001; Febbraio et al. 2004) and in vitro (Scheler et al. 2013; Evers-van Gogh et al. 2015; Feng et al. 2015) . In accordance with previous data, increased release of IL-6 was observed in myotubes exposed to EPS (Lambernd et al. 2012; Farmawati et al. 2013; Scheler et al. 2013; Christensen et al. 2015; Feng et al. 2015) , which indicates that in addition to the hypertrophy of muscle cells, our in vitro exercise model recapitulates another important exercise-induced physiological event. Even though the primary aim of the present work was to demonstrate that the in vitro model induces the occurrence of a major physiological end-point to resistance exercise (morphological enlargement of muscle cells), we provided additional information about selected markers representing a snapshot of the hypertrophic process. First, EPS was associated with increased phosphorylation of mTOR, a master regulator of muscle protein synthesis, and increased phosphorylation of eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1). Phosphorylation of 4E-BP1 by mTOR releases eIF4E, which leads to the formation of the eIF4F complex, resulting in stimulation of translation initiation (Schiaffino & Mammucari, 2011; Qin et al. 2016) . In line with this, the suppression of protein synthesis by CHX prevented EPS-induced myotube hypertrophy, indicating that protein accretion is important for EPS-induced growth of human myotubes. In this study, there were no significant changes in the activation of another mTOR downstream target, 70 kDa ribosomal S6 kinase 1 (p70S6k1), which has previously been shown to be upregulated in response to increased contractile activity in rats (Thomson et al. 2008) and to resistance exercise in humans (Karlsson et al. 2004; Dreyer et al. 2006) . The contribution of p70S6k in the enlargement of human myotubes in response to EPS should be investigated further, because a change in the phosphorylation status of indirect markers of muscle hypertrophy is a transient phenomenon, providing only a snapshot in time within the frame of the complex process of muscle growth.
In this proof-of-concept study, we hypothesized that changes in phosphorylation status would occur early in the process of hypertrophy, before the occurrence of cell enlargement. However, it is important to highlight the fact that changes in phosphorylation status of specific factors might occur at other time points in the process of muscle hypertrophy. In this respect, the model presented here will allow us and others to conduct future studies with the specific aim of studying the pattern and time course of activation of factors involved in cellular hypertrophy.
A second event in support of the EPS-mediated phosphorylation of mTOR was the absence of upregulation of AMPK, a key cellular energy sensor (Jäger et al. 2007; Lambernd et al. 2012; Evers-van Gogh et al. 2015) . It has been suggested that while resistance exercise is linked with an upregulation of the mTOR pathway, adaptation of skeletal muscle to endurance exercise is promoted through the upregulation of the AMPK pathway. Thus, the selective activation of these two molecular sensors contributes to divergent adaptations occurring in human skeletal muscle in response to strength and endurance activities (Atherton et al. 2005) . Thus, we hypothesize that hypertrophy of muscle cells in response to our EPS protocol is favoured by the activation of mTOR without concomitant increase in AMPK phosphorylation.
A third event contributing to the morphological changes in EPS myotubes was the downregulation of myostatin gene expression. Myostatin is known to be a negative regulator of muscle mass (Taylor et al. 2001; Trendelenburg et al. 2009; Ten Broek et al. 2010) , and its downregulation has previously been associated with the enlargement of muscle fibres (Latres et al. 2015) . In this proof-of-concept study, the physiological end-point selected to assess cell hypertrophy was the morphological enlargement of muscle cells. This model of physiologically mediated muscle growth will be the basis for future studies aiming to assess the effects of EPS on other physiological end-points and to depict molecular events governing the hypertrophy of human muscle cells.
In conclusion, the present work shows that EPS combined with a subsequent resting period is an in vitro model for the induction of hypertrophy of human muscle cells, a physiological end-point mimicking the in vivo response of skeletal muscle to resistance exercise. This work provides a mechanistic model of physiologically mediated muscle growth, which can be used in future studies aiming to depict molecular events governing the hypertrophy of human muscle cells. participated in data analysis, interpretation and in manuscript drafting. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.
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Supplemental Video S1. EPS-induced contraction of fully differentiated human myotubes. Magnification ×40.
